The exosome surge is a masterclass in the limitations of static research. When a sector is poised to triple in value within a few years, the old model—commissioning a white paper, waiting for peer reviews, and synthesizing data over months—is more than just slow. It is a liability. The core failures are structural: Lagging Indicators: Traditional reports capture clinical...